Previously, MIR210HG has been demonstrated to be overexpressed in hepatocellular carcinoma (40), non-small cell lung cancer (NSCLC) (41), osteosarcoma (42), glioma (43) and chemoresistant pancreatic cancer (44). This evidence concerns the gene MIR210HG and central nervous system cancer.